Tissue Regenix Group Plc
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal … Read more
Tissue Regenix Group Plc (TRX) - Total Assets
Latest total assets as of June 2025: GBX47.19 Million GBX
Based on the latest financial reports, Tissue Regenix Group Plc (TRX) holds total assets worth GBX47.19 Million GBX as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tissue Regenix Group Plc - Total Assets Trend (2007–2024)
This chart illustrates how Tissue Regenix Group Plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tissue Regenix Group Plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Tissue Regenix Group Plc's total assets of GBX47.19 Million consist of 46.9% current assets and 53.1% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 4.1% |
| Accounts Receivable | GBX4.38 Million | 9.7% |
| Inventory | GBX14.01 Million | 30.9% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX4.18 Million | 9.2% |
| Goodwill | GBX11.59 Million | 25.6% |
Asset Composition Trend (2007–2024)
This chart illustrates how Tissue Regenix Group Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tissue Regenix Group Plc's current assets represent 46.9% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2024, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 30.9% of total assets.
Tissue Regenix Group Plc Competitors by Total Assets
Key competitors of Tissue Regenix Group Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Tissue Regenix Group Plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Tissue Regenix Group Plc generates 0.63x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tissue Regenix Group Plc is currently not profitable relative to its asset base.
Tissue Regenix Group Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 3.74 | 5.48 |
| Quick Ratio | 0.77 | 1.47 | 4.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX14.88 Million | GBX 15.34 Million | GBX 19.02 Million |
Tissue Regenix Group Plc - Advanced Valuation Insights
This section examines the relationship between Tissue Regenix Group Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.24 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | GBX45.35 Million |
| Market Capitalization | $507.31 USD |
Valuation Analysis
Below Book Valuation: The market values Tissue Regenix Group Plc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tissue Regenix Group Plc's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tissue Regenix Group Plc (2007–2024)
The table below shows the annual total assets of Tissue Regenix Group Plc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX45.35 Million | +4.86% |
| 2023-12-31 | GBX43.24 Million | +12.98% |
| 2022-12-31 | GBX38.27 Million | +12.15% |
| 2021-12-31 | GBX34.13 Million | -7.09% |
| 2020-12-31 | GBX36.73 Million | +20.45% |
| 2019-12-31 | GBX30.50 Million | -19.03% |
| 2018-12-31 | GBX37.66 Million | -17.70% |
| 2018-01-31 | GBX45.76 Million | 0.00% |
| 2017-12-31 | GBX45.76 Million | +236.46% |
| 2016-12-31 | GBX13.60 Million | -58.83% |
| 2016-01-31 | GBX33.04 Million | +160.69% |
| 2015-01-31 | GBX12.67 Million | -61.74% |
| 2014-01-31 | GBX33.13 Million | -16.62% |
| 2013-01-31 | GBX39.73 Million | -11.32% |
| 2012-01-31 | GBX44.80 Million | +337.46% |
| 2011-01-31 | GBX10.24 Million | +175.46% |
| 2010-01-31 | GBX3.72 Million | +0.60% |
| 2009-01-31 | GBX3.70 Million | -62.17% |
| 2008-01-31 | GBX9.77 Million | +69.84% |
| 2007-01-31 | GBX5.75 Million | -- |